BACKGROUND AND PURPOSE: In patients with acute ischemic stroke and atrial fibrillation, treatment with low molecular weight heparin increases early hemorrhagic risk without reducing early recurrence, and there is limited data comparing warfarin to direct oral anticoagulant (DOAC) therapy. We aim to compare the effects of the treatments above on the risk of 90-day recurrent ischemic events and delayed symptomatic intracranial hemorrhage. METHODS: We included consecutive patients with acute ischemic stroke and atrial fibrillation from the IAC (Initiation of Anticoagulation after Cardioembolic) stroke study pooling data from stroke registries of 8 comprehensive stroke centers across the United States. We compared recurrent ischemic events and delayed symptomatic intracranial hemorrhage between each of the following groups in separate Cox-regression analyses: (1) DOAC versus warfarin and (2) bridging with heparin/low molecular weight heparin versus no bridging, adjusting for pertinent confounders to test these associations. RESULTS: We identified 1289 patients who met the bridging versus no bridging analysis inclusion criteria and 1251 patients who met the DOAC versus warfarin analysis inclusion criteria. In adjusted Cox-regression models, bridging (versus no bridging) treatment was associated with a high risk of delayed symptomatic intracranial hemorrhage (hazard ratio, 2.74 [95% CI, 1.01-7.42]) but a similar rate of recurrent ischemic events (hazard ratio, 1.23 [95% CI, 0.63-2.40]). Furthermore, DOAC (versus warfarin) treatment was associated with a lower risk of recurrent ischemic events (hazard ratio, 0.51 [95% CI, 0.29-0.87]) but not delayed symptomatic intracranial hemorrhage (hazard ratio, 0.57 [95% CI, 0.22-1.48]). CONCLUSIONS: Our study suggests that patients with ischemic stroke and atrial fibrillation would benefit from the initiation of a DOAC without bridging therapy. Due to our study limitations, these findings should be interpreted with caution pending confirmation from large prospective studies.
BACKGROUND AND PURPOSE: In patients with acute ischemic stroke and atrial fibrillation, treatment with low molecular weight heparin increases early hemorrhagic risk without reducing early recurrence, and there is limited data comparing warfarin to direct oral anticoagulant (DOAC) therapy. We aim to compare the effects of the treatments above on the risk of 90-day recurrent ischemic events and delayed symptomatic intracranial hemorrhage. METHODS: We included consecutive patients with acute ischemic stroke and atrial fibrillation from the IAC (Initiation of Anticoagulation after Cardioembolic) stroke study pooling data from stroke registries of 8 comprehensive stroke centers across the United States. We compared recurrent ischemic events and delayed symptomatic intracranial hemorrhage between each of the following groups in separate Cox-regression analyses: (1) DOAC versus warfarin and (2) bridging with heparin/low molecular weight heparin versus no bridging, adjusting for pertinent confounders to test these associations. RESULTS: We identified 1289 patients who met the bridging versus no bridging analysis inclusion criteria and 1251 patients who met the DOAC versus warfarin analysis inclusion criteria. In adjusted Cox-regression models, bridging (versus no bridging) treatment was associated with a high risk of delayed symptomatic intracranial hemorrhage (hazard ratio, 2.74 [95% CI, 1.01-7.42]) but a similar rate of recurrent ischemic events (hazard ratio, 1.23 [95% CI, 0.63-2.40]). Furthermore, DOAC (versus warfarin) treatment was associated with a lower risk of recurrent ischemic events (hazard ratio, 0.51 [95% CI, 0.29-0.87]) but not delayed symptomatic intracranial hemorrhage (hazard ratio, 0.57 [95% CI, 0.22-1.48]). CONCLUSIONS: Our study suggests that patients with ischemic stroke and atrial fibrillation would benefit from the initiation of a DOAC without bridging therapy. Due to our study limitations, these findings should be interpreted with caution pending confirmation from large prospective studies.
Authors: Walter N Kernan; Bruce Ovbiagele; Henry R Black; Dawn M Bravata; Marc I Chimowitz; Michael D Ezekowitz; Margaret C Fang; Marc Fisher; Karen L Furie; Donald V Heck; S Claiborne Clay Johnston; Scott E Kasner; Steven J Kittner; Pamela H Mitchell; Michael W Rich; DeJuran Richardson; Lee H Schwamm; John A Wilson Journal: Stroke Date: 2014-05-01 Impact factor: 7.914
Authors: Christian T Ruff; Robert P Giugliano; Eugene Braunwald; Elaine B Hoffman; Naveen Deenadayalu; Michael D Ezekowitz; A John Camm; Jeffrey I Weitz; Basil S Lewis; Alexander Parkhomenko; Takeshi Yamashita; Elliott M Antman Journal: Lancet Date: 2013-12-04 Impact factor: 79.321
Authors: Shadi Yaghi; Joshua Z Willey; Brett Cucchiara; Joshua N Goldstein; Nicole R Gonzales; Pooja Khatri; Louis J Kim; Stephan A Mayer; Kevin N Sheth; Lee H Schwamm Journal: Stroke Date: 2017-11-02 Impact factor: 7.914
Authors: Ying Xian; Haolin Xu; Emily C O'Brien; Shreyansh Shah; Laine Thomas; Michael J Pencina; Gregg C Fonarow; DaiWai M Olson; Lee H Schwamm; Deepak L Bhatt; Eric E Smith; Deidre Hannah; Lesley Maisch; Barbara L Lytle; Eric D Peterson; Adrian F Hernandez Journal: JAMA Neurol Date: 2019-10-01 Impact factor: 18.302
Authors: Shadi Yaghi; Nils Henninger; James A Giles; Christopher Leon Guerrero; Eva Mistry; Ava L Liberman; Daniyal Asad; Angela Liu; Muhammad Nagy; Ashutosh Kaushal; Idrees Azher; Brian Mac Grory; Hiba Fakhri; Kiersten Brown Espaillat; Hemanth Pasupuleti; Heather Martin; Jose Tan; Manivannan Veerasamy; Charles Esenwa; Natalie Cheng; Khadean Moncrieffe; Iman Moeini-Naghani; Mithilesh Siddu; Erica Scher; Tushar Trivedi; Karen L Furie; Salah G Keyrouz; Amre Nouh; Adam de Havenon; Muhib Khan; Eric E Smith; M Edip Gurol Journal: J Neurol Neurosurg Psychiatry Date: 2021-04-26 Impact factor: 13.654
Authors: Moisés F Molina-Fuentes; Rotraud Neumann; Wilhelm Behringer; Marcus Franz; P Christian Schulze; Otto W Witte; Albrecht Günther; Carsten Klingner; Lukas Lehmkuhl; Beatrice Steiniger; Ulf Teichgräber; J E Rod; Thomas E Mayer Journal: Clin Neuroradiol Date: 2021-08-11 Impact factor: 3.649
Authors: Lina Palaiodimou; Maria-Ioanna Stefanou; Aristeidis H Katsanos; Maurizio Paciaroni; Simona Sacco; Gian Marco De Marchis; Ashkan Shoamanesh; Konark Malhotra; Diana Aguiar de Sousa; Vaia Lambadiari; Maria Kantzanou; Sofia Vassilopoulou; Konstantinos Toutouzas; Dimitrios K Filippou; David J Seiffge; Georgios Tsivgoulis Journal: J Clin Med Date: 2022-08-25 Impact factor: 4.964
Authors: Shadi Yaghi; Eva Mistry; Adam de Havenon; Christopher R Leon Guerrero; Amre Nouh; Ava L Liberman; James Giles; Angela Liu; Muhammad Nagy; Ashutosh Kaushal; Idrees Azher; Brian Mac Grory; Hiba Fakhri; Kiersten Brown Espaillat; Syed Daniyal Asad; Hemanth Pasupuleti; Heather Martin; Jose Tan; Manivannan Veerasamy; Charles Esenwa; Natalie Cheng; Khadean Moncrieffe; Iman Moeini-Naghani; Mithilesh Siddu; Erica Scher; Tushar Trivedi; Teddy Wu; Muhib Khan; Salah Keyrouz; Karen Furie; Nils Henninger Journal: J Am Heart Assoc Date: 2021-07-29 Impact factor: 5.501